Featured Research

from universities, journals, and other organizations

Dangers of chemotherapy regimen for bladder cancer patients uncovered by clinical trial

Date:
May 30, 2014
Source:
Fox Chase Cancer Center
Summary:
Patients with muscle-invasive bladder cancer often benefit from chemotherapy before surgery to remove the tumor, but a test of one regimen by researchers was halted when too many people experienced serious side effects such as heart attacks and blood clots in the legs and lungs.

Patients with muscle-invasive bladder cancer often benefit from chemotherapy before surgery to remove the tumor, but a test of one regimen by researchers at Fox Chase Cancer Center was halted when too many people experienced serious side effects such as heart attacks and blood clots in the legs and lungs.

All of the 31 patients included in the study received a combination of gemcitabine and cisplatin, two drugs normally administered for 12 weeks before surgery to remove the tumors. This became the standard of care after one study looked back, retrospectively, at a their experience with a group of patients who had already received the drugs over 12 weeks and found that more than one-quarter saw their tumors disappear before surgery. Although this is the standard of care, no one had yet followed a group of patients taking these drugs from the start -- known as a "prospective" study -- which is the best way to test how well the treatment works and to uncover any issues, said Dr. Plimack.

"It's important to prospectively investigate both the activity and the potential side effects of these two chemotherapy drugs in patients with bladder cancer," said Elizabeth R. Plimack, MD, MS, Attending Physician the Department of Medical Oncology at Fox Chase Cancer, who reported these findings during the 50th Annual Meeting of the American Society of Clinical Oncology. "In patients who may be cured of their cancers, chemotherapy regimens that cause blood clots and other complications may delay or prevent life-saving surgery."

In Dr. Plimack's study, she and her colleagues gave patients gemcitabine and cisplatin over 6 weeks, rather than the usual 12. "Hitting tumors with chemotherapy more frequently might be more effective, and for patients who don't respond, a shorter regimen causes less of a delay in surgery," said Dr. Plimack, "and patients spend less of their life in cancer treatment."

But Dr. Plimack and her colleagues had to stop the phase II clinical trial before it was complete after 7 patients (23%) experienced serious cardiovascular events such as stroke, heart attack, and potentially deadly blood clots in the lungs or legs.

Even though gemcitabine is known to increase the risk of cardiovascular problems, she and her colleagues were "surprised" to see so many patients were affected. It's possible that condensing the doses into 6 weeks caused problems, but that's not the only explanation, said Dr. Plimack. "Two of the most severe cardiovascular events occurred after one treatment, so the dosing schedule was not the only factor here."

Gemcitabine is a frequently administered drug, so it is critical that researchers continue to follow patients receiving it, said Dr. Plimack. "In the meantime, patients who have concerns about taking gemcitabine should consult their doctors about their individual plan."


Story Source:

The above story is based on materials provided by Fox Chase Cancer Center. Note: Materials may be edited for content and length.


Cite This Page:

Fox Chase Cancer Center. "Dangers of chemotherapy regimen for bladder cancer patients uncovered by clinical trial." ScienceDaily. ScienceDaily, 30 May 2014. <www.sciencedaily.com/releases/2014/05/140530133346.htm>.
Fox Chase Cancer Center. (2014, May 30). Dangers of chemotherapy regimen for bladder cancer patients uncovered by clinical trial. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2014/05/140530133346.htm
Fox Chase Cancer Center. "Dangers of chemotherapy regimen for bladder cancer patients uncovered by clinical trial." ScienceDaily. www.sciencedaily.com/releases/2014/05/140530133346.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins